Efficacy and Safety of ATL-962 in Obese Diabetics

• Status: Completed
• Trial end date: 2005-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate whether ATL-962 induces weight loss in diabetic patients and whether its safety and tolerability profile is superior to that of orlistat in such patients

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alizyme
• Treatments: Orlistat

Criteria

Inclusion Criteria:

• Type II diabetes

• Body mass index 28-45kg/m2

• HbA1c 6%-10%

Exclusion Criteria:

• Significant weight loss in the previous 3 months

• Weight gain during the run-in period

• Other serious systemic conditions, except controlled hypertension, mild asthma, and primary hypothyroidism

• History of GI disorders

• Previous surgery for weight loss